Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases

The monoamine model of depression has long formed the basis of drug development but fails to explain treatment resistance or associations with stress or inflammation. Recent animal research, clinical trials of ketamine (a glutamate receptor antagonist), neuroimaging research, and microbiome studies...

Descripción completa

Detalles Bibliográficos
Autores principales: McGrath, Thomas, Baskerville, Richard, Rogero, Marcelo, Castell, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912368/
https://www.ncbi.nlm.nih.gov/pubmed/35267893
http://dx.doi.org/10.3390/nu14050917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912368/
https://www.ncbi.nlm.nih.gov/pubmed/35267893
http://dx.doi.org/10.3390/nu14050917

Ejemplares similares